B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE
Clinical trials for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE trials appear
Sign up with your email to follow new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy drug blinatumomab aims to boost leukemia survival in major trial
Disease control OngoingThis Phase III trial is testing whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a newly diagnosed type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 participants are randomly assigned to rece…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy aims to deepen remissions in tough leukemia
Disease control OngoingThis phase 2 trial tests whether adding the targeted antibody tafasitamab to a standard chemotherapy regimen (DA-EPOCH, with or without rituximab) can improve outcomes for adults newly diagnosed with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL). Th…
Matched conditions: B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC